Last reviewed · How we verify
LOXIGLUMIDE — Competitive Intelligence Brief
phase 2
loxiglumide
Cholecystokinin receptor type A, Cholecystokinin receptor type A
Gastroenterology
Small molecule
Live · refreshed every 30 min
Target snapshot
LOXIGLUMIDE (LOXIGLUMIDE). Loxiglumide works by binding to the cholecystokinin receptor type A, which helps to slow down gastric emptying and reduce symptoms of certain gastrointestinal disorders.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LOXIGLUMIDE TARGET | LOXIGLUMIDE | phase 2 | loxiglumide | Cholecystokinin receptor type A, Cholecystokinin receptor type A | ||
| D-Loxiglumide | DEXLOXIGLUMIDE | phase 3 | dexloxiglumide | Cholecystokinin receptor type A |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (loxiglumide class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LOXIGLUMIDE CI watch — RSS
- LOXIGLUMIDE CI watch — Atom
- LOXIGLUMIDE CI watch — JSON
- LOXIGLUMIDE alone — RSS
- Whole loxiglumide class — RSS
Cite this brief
Drug Landscape (2026). LOXIGLUMIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/loxiglumide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing